---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-152946"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T16:07:16.441758+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phathom prices public offering of 11.125M shares at $11.75/share for ~$130.7M gross

## Summary
- Offering of 11,125,000 shares at $11.75/share; gross proceeds ~$130.7M.
- Underwriters have 30-day option to purchase up to 1,668,750 additional shares.
- Net proceeds ~$122.4M ($140.8M if option exercised) to fund vonoprazan clinical dev., pre-commercial, and working capital.
- Offering expected to close May 26, 2023; Jefferies and Evercore ISI act as joint bookrunners.

## SEC filing metadata
- accession: 0001193125-23-152946
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523152946/0001193125-23-152946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523152946/d452618d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-152946
- JSON: https://secwatch.observer/filing/0001193125-23-152946.json
- Plain text: https://secwatch.observer/filing/0001193125-23-152946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.